Please assess the completion status of the following clinical trial:

Trial Title: Chronic Kidney Disease (CKD) Platelet Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females, aged 18-91 years~2. Ability to understand and sign informed consent after the nature of the study has been fully explained~3. CKD participants: Non-dialysis CKD patients: Presence of CKD with an estimated GFR of \<30 mL/min/1.73 m2 for a period of ≥3 months, as defined by the National Kidney Foundation (NKF) and determined with the CKD-EPI creatinine-based formula~4. Controls with normal kidney function: participants with an estimated GFR \>90 mL/min/1.73 m2 as determined by the CKD-EPI creatinine-based formula and a urine albumin-to-creatinine ratio \<30 mg/g as defined by the National Kidney Foundation~Exclusion Criteria:~* No healthcare power of attorney to sign informed consent~* Unwillingness or inability to participate in the protocol or comply with any of its components.~* Subjects unable or unwilling to stop taking:~  * Aspirin and other antithrombotic agents, like cilostazol, ranolazine, aggrenox, prasugrel, warfarin, xarelto, pradaxa, eliquis.~ * Glycoprotein IIb/IIIa antagonist (abciximab-ReoPro, eptifibatide-Integrilin, tirofiban-Aggrastal)~ * NSAIDs and PPIs~ * Fish oil, Vitamin E and herbal supplements~* Acute kidney injury superimposed on CKD~* Kidney transplant or any other solid organ transplant recipient~* End-stage kidney disease on maintenance dialysis (peritoneal or hemodialysis)~* Nephrotic syndrome defined as nephrotic range proteinuria, hypoalbuminemia, hyperlipidemia and generalized edema~* Recent hospitalization or surgery \<3 months~* Acute coronary or cerebrovascular event in the last 12 months~* Blood dyscrasias, active bleeding, or bleeding diathesis~* Gastrointestinal bleeding in the last 6 months~* Recent treatment (\<30 days) with a glycoprotein IIb/IIIa antagonist (Integrelin).~* Hematocrit \<25%, white blood cell count \>20,000/μL, or platelet count \<50,000/μL~* Any active malignancy or liver disease.~* Pregnancy~* Positive urine pregnancy test in a woman of childbearing potential prior to study entry. A female of childbearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:~  * Has not undergone a hysterectomy or bilateral oophorectomy; or~ * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).~* Patients must not be nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 91 Years
- Healthy Volunteers: t

Study Arms:
- CKD-Ticagrelor (Type: EXPERIMENTAL): Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d
- CKD-Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d
- Control-ticagrelor (Type: ACTIVE_COMPARATOR): Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).